We have a diverse pipeline of multi-targeted therapies in development for both inflammatory disease and oncology. In 2019, we completed enrollment of a Phase 1 healthy volunteer study for ALPN-101. Initial data were presented at the 2019 American Society of Hematology Annual Meeting. ‘BALANCE’, a Phase 1b/2 trial in acute graft versus host disease (GVHD) is now open for enrollment. ALPN-202 has NEON-1, a Phase 1 trial in advanced malignancies, now open for enrollment.